AegirBio
AegirBio AB is a Swedish diagnostics company based in Lund that specializes in developing tests to monitor and optimize the dosing of biological drugs. The company's focus is on therapeutic drug monitoring for biologic therapies used in autoimmune diseases, oncology, and neurology. AegirBio offers a unique, patented technology platform, including the moNATor test, which is the first dose-monitoring laboratory test for multiple sclerosis, aimed at healthcare professionals and patients. Additionally, the company's product lineup features Veritope technology, which detects intact natalizumab in multiple sclerosis, and the MagniaReader, designed for research and veterinary applications.
Viraspec AB, founded in 2020 and based in Lund, Sweden, specializes in developing and commercializing rapid diagnostic tests for COVID-19. The company focuses on point-of-care testing, utilizing a simple and robust platform that analyzes blood and saliva samples to detect antibodies and the virus itself. Viraspec's diagnostic platform features a test device that collects blood samples and provides results through an indicator, facilitating quicker, more accurate, and cost-effective testing for patients. As a subsidiary of AegirBio AB, Viraspec aims to enhance the efficiency of COVID-19 diagnostics, contributing to global efforts in managing the pandemic.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.